Building precision therapeutic platforms that create measurable value for every stakeholder — from the clinician at the bedside to the patient in recovery, the payer managing cost, and the caregiver providing continuity of care.
Vector Science & Therapeutics is building precision therapeutic platforms that matter to every stakeholder in the care continuum. Physicians gain a site-directed tool that performs where systemic therapy cannot. Clinicians gain confidence in durable, localized delivery. Patients gain recovery with fewer systemic trade-offs. Payers gain interventions designed to reduce downstream burden. Caregivers gain therapies that work across the full arc of patient care. We invite investors and institutional partners to join us in building platforms with that reach.
Data-informed formulations and devices that respond intelligently to tissue conditions.
Precisely directed therapies guided to the exact anatomical target site with active transdermal platforms.
Long-lasting therapeutic effects that support true musculoskeletal tissue regeneration and durable healing.
Targeted post-surgical and injury recovery applications where site-directed, non-opioid intervention can dramatically reduce recovery time and systemic drug burden.
Long-term musculoskeletal conditions including osteoarthritis and chronic pain disorders — markets where sustained, localized therapy offers a compelling alternative to systemic medications.
Vector Science & Therapeutics is advancing toward a public listing on the TSX Venture Exchange (TSXV). In October 2025, we announced a definitive agreement for a reverse merger with OpenSesame Acquisition Corp. — a pivotal step toward broad commercialization of our breakthrough platforms.
For the latest corporate updates and milestones, please see our News page or reach out to investor relations directly.